Daniel Silverman MD, PhDHead, Neuronuclear Imaging Section, Ahmanson Translational Imaging Division; Director, Brain Wellness and PET Consultation Services; Professor, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
Daniel H. Silverman, MD, PhD, is Head of the Neuronuclear Imaging Section of the Ahmanson Translational Imaging Division at UCLA Medical Center, Executive Committee member of the UCLA Alzheimer's Disease Center, Director of the UCLA Brain Wellness consultation service and NeuroPET Clinics, and Professor in the Department of Molecular and Medical Pharmacology, in the School of Medicine at the University of California, Los Angeles. He previously served as Editor of PET in the Evaluation of Alzheimer's Disease and Related Disorders,(Springer, New York, 2009), the first published textbook devoted exclusively to the role of positron emission tomography in assessment of neurodegenerative disorders. He obtained his Ph.D. in Biological Chemistry at Harvard University, postdoctoral research training in Biochemistry and Molecular Pharmacology at Harvard Medical School, his M.D. from The Ohio State University College of Medicine, and subsequently completed post-M.D. training at UCLA, before obtaining certification from both the American Board of Internal Medicine and the American Board of Nuclear Medicine.
Professor, Molecular & Medical Pharmacology
Attending Physician, UCLA Health Nuclear Medicine Services
Head, Neuronuclear Imaging Section
Director, UCLA NeuroPET Clinics